The Development of mRNA Vaccines
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "DNA and mRNA Vaccines".
Deadline for manuscript submissions: 31 December 2025 | Viewed by 266
Special Issue Editors
Interests: infectious disease; mRNA vaccine; coronavirus; immunology; adjuvant
Special Issues, Collections and Topics in MDPI journals
Interests: vaccine; virus–host interactions; antiviral immunity; coronavirus; enterovirus
Interests: nucleic acid therapeutics; lipid nanoparticle; targeting delivery; cancer; immunoregulation; vaccines
Special Issue Information
Dear Colleagues,
mRNA vaccines have emerged as a transformative platform in modern medicine, demonstrating remarkable success in combating infectious diseases, such as COVID-19 and RSV. This Special Issue aims to explore the latest advancements in mRNA vaccine research, encompassing a wide range of applications, from infectious disease prevention to tumor immunity. Topics of interest include innovative mRNA delivery systems that enhance stability and efficiency, novel vaccine designs targeting emerging pathogens and cancer antigens, and the development of next-generation adjuvants to optimize immune responses. Additionally, we welcome studies addressing manufacturing scalability, regulatory challenges, and strategies to broaden mRNA vaccine accessibility. By showcasing cutting-edge research, this Special Issue seeks to advance the field and inspire new approaches to address global health challenges.
Dr. Minghui Yang
Dr. Yuming Li
Dr. Bo Hu
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- nanoparticle delivery system
- mRNA vaccines
- infectious disease
- tumor immunity
- adjuvant
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
